The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells

Table 2 Summarizes results of MTT-tests in different rhabdoid tumor cell lines (A204, G401, BT16) treated with HDAC-inhibitors (SAHA, TSA, M344) or doxorubicin as single compounds or in combinations of both compounds

Cell line	Compound 1	Compound 2	IC 50 μM	m	CI	R²
A204	SAHA	---------------	24.72	0.6	---------------	0.72
A204	DOXO	---------------	6.48	0.37	---------------	0.72
A204	DOXO	SAHA	0.16	0.22	0.02	0.76
G401	SAHA	---------------	31.82	0.44	---------------	0.87
G401	DOXO	---------------	0.67	0.38	---------------	0.77
G401	DOXO	SAHA	0.03	0.17	0.03	0.85
BT16	SAHA	---------------	8.39	0.64	---------------	0.93
BT16	DOXO	---------------	0.13	0.18	---------------	0.83
BT16	DOXO	SAHA	0.003	0.2	0.02	0.81

The CI values have been determined at the respective IC50 concentration. CI < 1 indicates synergism. R² denotes the coefficient of determination of the linear regression in the median effect plot.

ISSN: 1471-2407